Balaji Amines Ltd Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company anticipates significant growth and favorable market conditions in FY 2024-25.
- Standalone volume growth is guided at a minimum of 10% conservatively, excluding expansions.
- Demand improvement observed with 8.25% volume growth year-on-year; expected to continue improving in coming quarters.
- Capacity expansions (e.g., methylamine plant, specialty chemicals unit) will support volume and revenue growth.
- New phases of CAPEX (total ~Rs. 750 crores) aimed at specialty chemicals expected to increase revenues substantially.
- Solar power plant and captive power initiatives will improve cost efficiency and sustainability.
- Specialty chemicals volume recovery is expected alongside sustained demand in amines and derivatives.
- Improved utilization of DMF and methylamine plants will boost production and exports.
- FY 2024-25 outlook is optimistic, targeting sustained revenue and volume growth backed by new capacities and market recovery.
See what Balaji Amines Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- For the Rs. 750 crores CAPEX on the BSC Unit II expansion:
- - The first phase (Rs. 300-400 crores) will be funded 99% through internal accruals.
- - For the second phase, depending on first phase operations, the company may need Rs. 50-100 crores debt borrowing.
- Regarding IPO plans:
- - No specific updates were provided other than that the company had planned an IPO earlier.
- Overall, no immediate large-scale equity fundraising mentioned; minor debt could be used for the second CAPEX phase.
See what Balaji Amines Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing CAPEX of Rs. 750 crores for Balaji Specialty Chemicals (BSC) Unit II, split into two phases (Rs. 300-400 crores first phase, Rs. 350 crores second phase), targeting products like sodium cyanide, triethyl orthoformate, EDTA derivatives, and others.
- Methylamines plant expansion of 40,000 tons capacity, expected to be commissioned by December 2024.
- New plant for Electronic grade Dimethyl Carbonate (DMC) with 15,000 MT per annum capacity, targeting the India EV battery market, commissioning in FY24-25.
- Dimethyl ether (DME) manufacturing project at Unit IV, expected launch by March 2025.
- Proposed plants for N-Methyl Morpholine (3,000 TPA), N-(n-butyl) Thiophosphoric Triamide (NBPT, 2,500 TPA), and isopropylamine (modification of existing Ethylamine plant).
- New 20 MW solar power plant at Solapur, Maharashtra; phase 1 with 8 MW expected operational by December 2024, aiming for up to 100% power from solar post expansions.
- Hotel expansion with 40 additional rooms costing Rs. 30-35 crores.
Track Balaji Amines Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Management anticipates minimum standalone volume growth of 10% for FY '25, conservatively.
- EBITDA margins are expected to range between 21% to 24% going forward.
- Specialty Chemicals and amines derivatives expansions (e.g., new methylamine and dimethyl ether plants) should bolster growth.
- New product launches and capacity expansions (e.g., BSC Unit II with Rs. 750 crore CAPEX) are set to drive incremental revenues, estimated to cross INR 1,000 crores from Unit II alone.
- Increased captive consumption through expansions (e.g., methylamines) will improve margins and profitability.
- Solar power plant commissioning by year-end aims to reduce power costs and carbon footprint, aiding cost-efficient operations.
- The company remains debt-free, enabling financial stability for sustainable growth.
- Overall, management expresses confidence in sustained growth, improved margins, and higher EPS buoyed by capacity additions and favorable market conditions.
Order book
How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Balaji Amines Ltd rank in Chemicals & Petrochemicals?
Compare Balaji Amines Ltd against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Balaji Amines Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…